The published Phase 2 obesity trial measured weight change at 24 weeks and again at 48 weeks, reporting dose-dependent mean reductions of up to 17.5% and up to 24.2% respectively
Alongside these medical advancements, there is a growing recognition of the need to address the broader social and environmental drivers of obesity
[ Randomized controlled trial, general recommendation ] 4
Under global fitting, k off and K D were estimated directly, with k on calculated as k off /K D
Key Points Genetics probably plays a part in GLP-1 response, but it is not the main practical explanation in most cases A new Nature paper found GLP1R and GIPR variants associated with efficacy and side effects, but effect sizes are modest Non-genetic factors drug choice, dose, duration, sex, diabetes status still explain more variation than genetics Current evidence does not justify routine genetic testing before prescribing semaglutide or tirzepatide Most apparent non-responders have correctable clinical reasons for poor response If you are wondering why GLP-1 drugs work better for some people , the short answer is this: genetics probably plays a part, but it is not the main practical explanation in most cases
For a deeper breakdown of what to expect month by month, read our guide on how long glutathione takes to lighten skin
